Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1999 Jun;80(8):1252–1258. doi: 10.1038/sj.bjc.6690493

Anti-tumour activity in vitro and in vivo of selective differentiating agents containing hydroxamate

L Qiu 1, M J Kelso 2, C Hansen 1, M L West 2, D P Fairlie 2, P G Parsons 1
PMCID: PMC2362353  PMID: 10376979

Abstract

A series of hydroxamates, which are not metalloprotease inhibitors, have been found to be selectively toxic to a range of transformed and human tumour cells without killing normal cells (fibroblasts, melanocytes) at the same concentrations. Within 24 h of treatment, drug action is characterized by morphological reversion of tumour cells to a more normal phenotype (dendritic morphology), and rapid and reversible acetylation of histone H4 in both tumour and normal cells. Two hydroxamates inhibited growth of xenografts of human melanoma cells in nude mice; resistance did not develop in vivo or in vitro. A third hydroxamate, trichostatin A, was active in vitro but became inactivated and had no anti-tumour activity in vivo. Development of dendritic morphology was found to be dependent upon phosphatase activity, RNA and protein synthesis. Proliferating hybrid clones of sensitive and resistant cells remained sensitive to ABHA, indicating a dominant-negative mechanism of sensitivity. Histone H4 hyperacetylation suggests that these agents act at the chromatin level. This work may lead to new drugs that are potent, and selective anti-tumour agents with low toxicity to normal cells. © 1999 Cancer Research Campaign

Keywords: differentiating agents, melanoma, histone acetylation

Full Text

The Full Text of this article is available as a PDF (458.4 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Andreeff M., Stone R., Michaeli J., Young C. W., Tong W. P., Sogoloff H., Ervin T., Kufe D., Rifkind R. A., Marks P. A. Hexamethylene bisacetamide in myelodysplastic syndrome and acute myelogenous leukemia: a phase II clinical trial with a differentiation-inducing agent. Blood. 1992 Nov 15;80(10):2604–2609. [PubMed] [Google Scholar]
  2. Beere H. M., Hickman J. A. Differentiation: a suitable strategy for cancer chemotherapy? Anticancer Drug Des. 1993 Aug;8(4):299–322. [PubMed] [Google Scholar]
  3. Boulikas T. A compilation and classification of DNA binding sites for protein transcription factors from vertebrates. Crit Rev Eukaryot Gene Expr. 1994;4(2-3):117–321. doi: 10.1615/critreveukargeneexpr.v4.i2-3.10. [DOI] [PubMed] [Google Scholar]
  4. Breslow R., Jursic B., Yan Z. F., Friedman E., Leng L., Ngo L., Rifkind R. A., Marks P. A. Potent cytodifferentiating agents related to hexamethylenebisacetamide. Proc Natl Acad Sci U S A. 1991 Jul 1;88(13):5542–5546. doi: 10.1073/pnas.88.13.5542. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Chen T. R. In situ detection of mycoplasma contamination in cell cultures by fluorescent Hoechst 33258 stain. Exp Cell Res. 1977 Feb;104(2):255–262. doi: 10.1016/0014-4827(77)90089-1. [DOI] [PubMed] [Google Scholar]
  6. Hoshikawa Y., Kwon H. J., Yoshida M., Horinouchi S., Beppu T. Trichostatin A induces morphological changes and gelsolin expression by inhibiting histone deacetylase in human carcinoma cell lines. Exp Cell Res. 1994 Sep;214(1):189–197. doi: 10.1006/excr.1994.1248. [DOI] [PubMed] [Google Scholar]
  7. Kijima M., Yoshida M., Sugita K., Horinouchi S., Beppu T. Trapoxin, an antitumor cyclic tetrapeptide, is an irreversible inhibitor of mammalian histone deacetylase. J Biol Chem. 1993 Oct 25;268(30):22429–22435. [PubMed] [Google Scholar]
  8. Kiyokawa H., Richon V. M., Rifkind R. A., Marks P. A. Suppression of cyclin-dependent kinase 4 during induced differentiation of erythroleukemia cells. Mol Cell Biol. 1994 Nov;14(11):7195–7203. doi: 10.1128/mcb.14.11.7195. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Marks P. A., Richon V. M., Kiyokawa H., Rifkind R. A. Inducing differentiation of transformed cells with hybrid polar compounds: a cell cycle-dependent process. Proc Natl Acad Sci U S A. 1994 Oct 25;91(22):10251–10254. doi: 10.1073/pnas.91.22.10251. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Maynard K., Parsons P. G. Cross-sensitivity of methylating agents, hydroxyurea, and methotrexate in human tumor cells of the Mer- phenotype. Cancer Res. 1986 Oct;46(10):5009–5013. [PubMed] [Google Scholar]
  11. McBain J. A., Eastman A., Nobel C. S., Mueller G. C. Apoptotic death in adenocarcinoma cell lines induced by butyrate and other histone deacetylase inhibitors. Biochem Pharmacol. 1997 May 9;53(9):1357–1368. doi: 10.1016/s0006-2952(96)00904-5. [DOI] [PubMed] [Google Scholar]
  12. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1983 Dec 16;65(1-2):55–63. doi: 10.1016/0022-1759(83)90303-4. [DOI] [PubMed] [Google Scholar]
  13. Musk P., Clark J. M., Thompson D., Dunn I. S., Christopherson R. I., Szabados E., Rose S. E., Parsons P. G. Purine deoxynucleoside metabolism in human melanoma cells with a high spontaneous mutation rate. Mutat Res. 1996 Feb 19;350(1):229–238. doi: 10.1016/0027-5107(95)00111-5. [DOI] [PubMed] [Google Scholar]
  14. Nakamura T., Okuyama S., Okamoto S., Nakajima T., Sekiya S., Oda K. Down-regulation of the cyclin A promoter in differentiating human embryonal carcinoma cells is mediated by depletion of ATF-1 and ATF-2 in the complex at the ATF/CRE site. Exp Cell Res. 1995 Feb;216(2):422–430. doi: 10.1006/excr.1995.1053. [DOI] [PubMed] [Google Scholar]
  15. Palitti F., Carotti D., Busiello V., Bendicenti A., Strom R., Di Girolamo M. DNA hypomethylation and differentiation in Friend leukemia cell variants. Biochim Biophys Acta. 1993 Oct 19;1216(1):50–54. doi: 10.1016/0167-4781(93)90036-d. [DOI] [PubMed] [Google Scholar]
  16. Parsons P. G., Favier D., McEwan M., Takahashi H., Jimbow K., Ito S. Action of cysteaminylphenols on human melanoma cells in vivo and in vitro: 4-S-cysteaminylphenol binds protein disulphide isomerase. Melanoma Res. 1991 Jun-Jul;1(2):97–104. doi: 10.1097/00008390-199106000-00004. [DOI] [PubMed] [Google Scholar]
  17. Parsons P. G., Hansen C., Fairlie D. P., West M. L., Danoy P. A., Sturm R. A., Dunn I. S., Pedley J., Ablett E. M. Tumor selectivity and transcriptional activation by azelaic bishydroxamic acid in human melanocytic cells. Biochem Pharmacol. 1997 Jun 1;53(11):1719–1724. doi: 10.1016/s0006-2952(97)00016-6. [DOI] [PubMed] [Google Scholar]
  18. Perrine S. P., Olivieri N. F., Faller D. V., Vichinsky E. P., Dover G. J., Ginder G. D. Butyrate derivatives. New agents for stimulating fetal globin production in the beta-globin disorders. Am J Pediatr Hematol Oncol. 1994 Feb;16(1):67–71. [PubMed] [Google Scholar]
  19. Rasmussen H. S., McCann P. P. Matrix metalloproteinase inhibition as a novel anticancer strategy: a review with special focus on batimastat and marimastat. Pharmacol Ther. 1997;75(1):69–75. doi: 10.1016/s0163-7258(97)00023-5. [DOI] [PubMed] [Google Scholar]
  20. Richon V. M., Emiliani S., Verdin E., Webb Y., Breslow R., Rifkind R. A., Marks P. A. A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. Proc Natl Acad Sci U S A. 1998 Mar 17;95(6):3003–3007. doi: 10.1073/pnas.95.6.3003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Richon V. M., Venta-Perez G. Changes in E2F DNA-binding activity during induced erythroid differentiation. Cell Growth Differ. 1996 Jan;7(1):31–42. [PubMed] [Google Scholar]
  22. Richon V. M., Webb Y., Merger R., Sheppard T., Jursic B., Ngo L., Civoli F., Breslow R., Rifkind R. A., Marks P. A. Second generation hybrid polar compounds are potent inducers of transformed cell differentiation. Proc Natl Acad Sci U S A. 1996 Jun 11;93(12):5705–5708. doi: 10.1073/pnas.93.12.5705. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Rifkind R. A., Richon V. M., Marks P. A. Induced differentiation, the cell cycle, and the treatment of cancer. Pharmacol Ther. 1996;69(2):97–102. doi: 10.1016/0163-7258(95)02044-6. [DOI] [PubMed] [Google Scholar]
  24. Rowinsky E. K., Conley B. A., Jones R. J., Spivak J. L., Auerbach M., Donehower R. C. Hexamethylene bisacetamide in myelodysplastic syndrome: effect of five-day exposure to maximal therapeutic concentrations. Leukemia. 1992 Jun;6(6):526–534. [PubMed] [Google Scholar]
  25. Saito S., Crissman H. A., Nishijima M., Kagabu T., Nishiya I., Cram L. S. Flow cytometric and biochemical analysis of dose-dependent effects of sodium butyrate on human endometrial adenocarcinoma cells. Cytometry. 1991;12(8):757–764. doi: 10.1002/cyto.990120810. [DOI] [PubMed] [Google Scholar]
  26. Schroy P. C., Rustgi A. K., Ikonomu E., Liu X. P., Polito J., Andry C., O'Keane J. C. Growth and intestinal differentiation are independently regulated in HT29 colon cancer cells. J Cell Physiol. 1994 Oct;161(1):111–123. doi: 10.1002/jcp.1041610114. [DOI] [PubMed] [Google Scholar]
  27. Stoker A., Dutta R. Protein tyrosine phosphatases and neural development. Bioessays. 1998 Jun;20(6):463–472. doi: 10.1002/(SICI)1521-1878(199806)20:6<463::AID-BIES4>3.0.CO;2-N. [DOI] [PubMed] [Google Scholar]
  28. Thyberg J., Hultgårdh-Nilsson A., Kallin B. Inhibitors of ADP-ribosylation suppress phenotypic modulation and proliferation of smooth muscle cells cultured from rat aorta. Differentiation. 1995 Nov;59(4):243–252. doi: 10.1046/j.1432-0436.1995.5940243.x. [DOI] [PubMed] [Google Scholar]
  29. Wang X., Hafezparast M., Masters J. R. Genetic basis of drug sensitivity in human testis tumour cells. Int J Cancer. 1996 Feb 8;65(4):426–431. doi: 10.1002/(SICI)1097-0215(19960208)65:4<426::AID-IJC5>3.0.CO;2-Z. [DOI] [PubMed] [Google Scholar]
  30. Wolffe A. P., Pruss D. Targeting chromatin disruption: Transcription regulators that acetylate histones. Cell. 1996 Mar 22;84(6):817–819. doi: 10.1016/s0092-8674(00)81059-4. [DOI] [PubMed] [Google Scholar]
  31. Yoshida M., Horinouchi S., Beppu T. Trichostatin A and trapoxin: novel chemical probes for the role of histone acetylation in chromatin structure and function. Bioessays. 1995 May;17(5):423–430. doi: 10.1002/bies.950170510. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES